Politics and Solutions . . Local collection of flower-picking price reduction DIP pay to appear on the supplies country to start the first shot

Text . . Linan October, high-value supplies national collection hit the first shot, the national version of the crown vein bracket centralized with the volume of procurement documents officially released.
this collection is made of cobalt chromium alloy or platinum chromium alloy, the drug is the coronary support of repamycin and its derivatives, the number of products is 27.
total number of intentional procurement in the first year of this year was 1.0747 million, of which 12 were intended to purchase enterprises and the procurement cycle was 2 years.
heart stent has always been a disaster area of medical corruption, with the collection of guns, it is expected that a large number of stents of inflated prices will be squeezed, the middle circulation of life and death, profits greatly reduced, the heart stent market shuffling in the immediate.
on the other side, drug collection across the country ushered in a "hundred flowers in full bloom", Anhui Province intends to 231 drugs centralized belt procurement negotiations, the use of multiple rounds of negotiations screening mechanism, Hunan 5 city joint belt volume procurement start, the first "spiral price reduction."
local collection is no longer dominated by a single city, but also in the form of bargaining negotiations have their own swings, quite characteristic.
In addition, the inter-provincial collection alliance is also in rapid development, Yuguiyun Xianggui 5 provinces / cities to carry out the alliance collection, Sichuan and other 8 provinces and regions of the health insurance bureau also announced the inter-provincial alliance drug collection work, collection varieties are mostly injections.
although there are still a large number of injections have not been consistent evaluation, but the clinical procurement of high amounts of injections has become the inter-provincial collection of "the main role", large-scale price reduction is inevitable.
the same time, CDE issued a notice, injection consistency evaluation supplementary information appeared in two cases of non-approval, the domestic injection market knockout accelerated.
In addition, the big data-based disease sub-payment method (DIP) in the reform of health insurance payment methods is also about to appear, the National Health Insurance Administration issued the "Regional Points Act Total Budget and Pay-by-Disease Value Pilot Work Programme", which clearly states that the eligible regions from March 2021 can start the actual payment first after filing;
can see the trend of medical insurance fee control, medical insurance fine management, will profoundly affect the hospital incentive mechanism and patients' medical expenses.
This month's heavyweight focus is: the State Drug Administration: by the end of this year to achieve the national drug and other key varieties traceability, anti-monopoly guidelines in the field of raw materials are about to be issued, the base drug catalog adjustment of new regulations outflow: do not consider corporate declarations, high-priced drugs can also be included, China introduced basic laws in the field of biosecurity ...